Enhanced neutralization potency of botulinum neurotoxin antibodies using a red blood cell-targeting fusion protein

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Adekar, Sharad P ^a,b,f   Segan, Andrew T ^a   Chen, Cindy ^a   Bermudez, Rodney ^b   Elias, M D ^c   Selling, Bernard H ^d   Kapadnis, B P ^e   Simpson, Lance L ^c   Simon, Paul M ^f   Dessain, Scott K ^a  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b Immunome Inc   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Impact Biologicals Inc   (United States)

^e UNIVERSITY OF PUNE   (India)

^f Augmenta Biologicals LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTISERUM; BOTULINUM ANTISERUM; BOTULINUM TOXIN A; GLYCOPHORIN A SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY STREPTAVIDIN FUSION PROTEIN; HYBRID PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 13A; MONOCLONAL ANTIBODY 30B; MONOCLONAL ANTIBODY 4LCA; MONOCLONAL ANTIBODY 6A; UNCLASSIFIED DRUG; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING AFFINITY; BIOTINYLATION; BOTULISM; CELL SURFACE; COMPLEX FORMATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; ERYTHROCYTE; FEMALE; IMMUNE ADHERENCE; LD 50; MOUSE; NONHUMAN; ANIMAL; BLOOD; IMMUNOLOGY; INJECTION; METABOLISM; METHODOLOGY; PROTEIN BINDING; SERODIAGNOSIS;

MURINAE; MUS; PRIMATES; RODENTIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BIOTINYLATION; BOTULINUM TOXINS, TYPE A; ERYTHROCYTES; FEMALE; INJECTIONS; MICE; NEUTRALIZATION TESTS; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS;

EID: 79952305409     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017491     Document Type: Article

References (31)

1. Simpson LL, (2004) Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 44: 167-193.
2. Ravichandran E, Al-Saleem FH, Ancharski DM, Elias MD, Singh AK, et al. (2007) Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 75: 3043-3054.
3. Al-Saleem FH, Ancharski DM, Ravichandran E, Joshi SG, Singh AK, et al. (2008) The role of systemic handling in the pathophysiologic actions of botulinum toxin. J Pharmacol Exp Ther 326: 856-863.
4. Dong M, Richards DA, Goodnough MC, Tepp WH, Johnson EA, et al. (2003) Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol 162: 1293-1303.
5. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, et al. (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312: 592-596.
6. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL, (2006) Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 354: 462-471.
7. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, et al. (2002) Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A 99: 11346-11350.
8. Ravichandran E, Gong Y, Al Saleem FH, Ancharski DM, Joshi SG, et al. (2006) An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther 318: 1343-1351.
9. Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, et al. (2005) Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun 73: 5450-5457.
10. Sepulveda J, Mukherjee J, Tzipori S, Simpson LL, Shoemaker CB, (2010) Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents. Infect Immun 78: 756-763.
11. Nelson RA Jr, (1953) The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis. Science 118: 733-737.
12. Takai T, (2005) Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol 25: 1-18.
13. Davies KA, Hird V, Stewart S, Sivolapenko GB, Jose P, et al. (1990) A study of in vivo immune complex formation and clearance in man. J Immunol 144: 4613-4620.
14. Davies KA, Peters AM, Beynon HL, Walport MJ, (1992) Immune complex processing in patients with systemic lupus erythematosus. In vivo imaging and clearance studies. J Clin Invest 90: 2075-2083.
15. Alexander JJ, Hack BK, Cunningham PN, Quigg RJ, (2001) A protein with characteristics of factor H is present on rodent platelets and functions as the immune adherence receptor. J Biol Chem 276: 32129-32135.
16. Taylor RP, Nardin A, Sutherland WM, (1997) Clearance of blood-borne pathogens mediated through bispecific monoclonal antibodies bound to the primate erythrocyte complement receptor. Cancer Immunol Immunother 45: 152-155.
17. Lindorfer MA, Hahn CS, Foley PL, Taylor RP, (2001) Heteropolymer-mediated clearance of immune complexes via erythrocyte CR1: mechanisms and applications. Immunol Rev 183: 10-24.
18. Pahler A, Hendrickson WA, Kolks MA, Argarana CE, Cantor CR, (1987) Characterization and crystallization of core streptavidin. J Biol Chem 262: 13933-13937.
19. Chasis JA, Mohandas N, (1992) Red blood cell glycophorins. Blood 80: 1869-1879.
20. Adekar SP, Jones RM, Elias MD, Al-Saleem FH, Root MJ, et al. (2008) A Human Monoclonal Antibody that Binds Serotype A Botulinum Neurotoxin. Hybridoma (Larchmt) 27: 11-17.
21. Adekar SP, Jones RM, Elias MD, Al-Saleem FH, Root MJ, et al. (2008) Hybridoma populations enriched for affinity-matured human IgGs yield high-affinity antibodies specific for botulinum neurotoxins. J Immunol Methods 333: 156-166.
22. Adekar SP, Takahashi T, Jones RM, Al-Saleem FH, Ancharski DM, et al. (2008) Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS ONE 3: e3023.
23. Spitzer D, Unsinger J, Bessler M, Atkinson JP, (2004) ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement. Mol Immunol 40: 911-919.
24. Sano T, Cantor CR, (1990) Cooperative biotin binding by streptavidin. Electrophoretic behavior and subunit association of streptavidin in the presence of 6 M urea. J Biol Chem 265: 3369-3373.
25. Takahashi T, Joshi SG, Al-Saleem F, Ancharski D, Singh A, et al. (2009) Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin. Vaccine 27: 2616-2624.
26. Eubanks LM, Hixon MS, Jin W, Hong S, Clancy CM, et al. (2007) An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci U S A 104: 2602-2607.
27. California Department of Health (2009) Summary Basis of Approval Botulinum Immune Globulin Intravenous (Human) BIG-IV. website: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm117169.pdf.
28. Cheng LW, Stanker LH, Henderson TD 2nd, Lou J, Marks JD, (2009) Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun 77: 4305-4313.
29. Mazuet C, Dano J, Popoff MR, Creminon C, Volland H, (2010) Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity. PLoS One 5: e12416.
30. Pier CL, Tepp WH, Bradshaw M, Johnson EA, Barbieri JT, et al. (2008) Recombinant holotoxoid vaccine against botulism. Infect Immun 76: 437-442.
31. Rummel A, Mahrhold S, Bigalke H, Binz T, (2004) The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol 51: 631-643.